PCF-Funded Research Inhibits Prostate Cancer Growth
New research, just published in Cancer Discovery, describes a new therapy with promising preclinical activity that is now being tested in clinical trials for very advanced prostate cancer patients. Early...Read More
Breaking News: FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
On Friday, December 18, 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, for adult patients with advanced prostate cancer. This is an important advance...Read More
New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer
PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have...Read More
Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel
Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA...Read More
Researchers Discover How a Gene Deletion Contributes to Prostate Cancer Growth
Original Press Release Issued by: Weill Cornell Medicine The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland,...Read More
New Study Identifies Another Opportunity for Precision Immunotherapy in Prostate Cancer
A new Prostate Cancer Foundation (PCF)-funded study published today in the scientific journal Cell has identified a new subtype of advanced prostate cancer – one which may be treatable with...Read More
New and More Sensitive Prostate Cancer Imaging on the Near Horizon
At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, promising results were reported from a phase 2/3 clinical trial testing the accuracy of a new prostate cancer imaging...Read More
PCF-funded investigators report progress on a promising new treatment for a highly lethal form of prostate cancer
Prostate cancer cells depend on androgens to grow and thrive. Because of this dependency, hormone therapy – the blockade of androgens and the androgen receptor (AR) – has been the...Read More
Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer
APRIL 2, 2018 -- Issued by Dana-Farber Cancer Institute. By sequencing DNA in more than 1,000 patient samples, researchers have identified a total of 97 genes significantly mutated in prostate...Read More
New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer
Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The...Read More